DEF 14A: LifeMD Seeks Stockholder Approval for Amended Equity Incentive Plan

LifeMD is asking stockholders to approve an amendment to its 2020 Equity and Incentive Plan to increase the number of shares available for issuance by 3,000,000.

Summary

• LifeMD is seeking stockholder approval to amend and restate its 2020 Equity and Incentive Plan to increase the maximum number of shares available for issuance by 3,000,000.
• The current plan, the Second Amended and Restated 2020 Plan, has a maximum of 5,100,000 shares available.
• As of December 31, 2023, there were 726,889 options and 3,194,375 restricted stock units outstanding under the existing plan.
• As of April 24, 2024, there were 554,667 options and 1,910,250 restricted shares outstanding under the existing plan.
• The proposed amendment would increase the baseline amount from 4,500,000 to 7,500,000 shares.
• If approved, the maximum number of shares available would be 8,100,000, including annual increases.
• The company believes that stock-based incentives are important for attracting, retaining, and rewarding employees, directors, and consultants.
• The amendment also extends the term of the plan from September 19, 2030, to April 29, 2034.
• The board recommends voting for the approval of the Third Amended and Restated 2020 Plan.
• The annual increase in future years is not expected to exceed 150,000 shares (or approximately 0.4% of the Company's currently issued and outstanding common stock under the current terms of the Second Amended and Restated 2020 Plan).

Sentiment

Score: 7

Explanation: The document is generally positive, focusing on the benefits of the equity incentive plan for attracting and retaining talent. However, there are potential risks associated with dilution, which tempers the overall sentiment.

Positives

• The increased share reserve will help LifeMD attract and retain talent by providing competitive equity incentives.
• The extension of the plan's term ensures the company can continue to use equity-based compensation for the long term.
• Stock-based incentives align the interests of employees, directors, and consultants with those of stockholders.

Negatives

• The increase in available shares could dilute existing stockholders' ownership if a large number of awards are granted.
• The document does not explicitly state any negative impacts, but increased share issuance always carries a potential dilution risk.

Risks

• Failure to obtain stockholder approval for the amended plan could limit LifeMD's ability to offer competitive equity compensation packages.
• Excessive dilution from equity awards could negatively impact the stock price and stockholder value.

Future Outlook

The company anticipates that the annual increase in future years is not expected to exceed 150,000 shares (or approximately 0.4% of the Company's currently issued and outstanding common stock under the current terms of the Second Amended and Restated 2020 Plan).

Management Comments

• The Board of Directors continues to believe that stock-based incentives are important factors in attracting, retaining and awarding officers, employees, directors and consultants and closely aligning their interests with those of our stockholders.
• The Board of Directors believes that increasing the number of shares available for issuance under the Second Amended and Restated 2020 Plan by 3,000,000 shares, which will be effected by increasing the Baseline Amount from 4,500,000 to 7,500,000 shares, is consistent with the Company's compensation philosophy (and with responsible compensation policies generally) and will preserve the Company's ability to attract and retain capable officers, employees, directors and consultants.

Industry Context

The use of equity incentive plans is a common practice in the technology and healthcare industries to attract and retain talent, aligning employee interests with those of shareholders.

Comparison to Industry Standards

• Many comparable companies in the tech and healthcare sectors utilize equity compensation plans to incentivize employees and align their interests with shareholders.
• The size of the share reserve increase (3,000,000 shares) and the annual increase (150,000 shares) should be evaluated against industry benchmarks for companies of similar size and growth stage.
• Companies like Teladoc Health, GoodRx, and Hims & Hers Health also rely on equity compensation to attract and retain key personnel.

Related Party Transactions

• Mr. Bhatia, a member of the Board of Directors, is a 3% owner of CRG Financial and serves on the board of directors of CRG Financial.
• During the years ended December 31, 2023 and 2022, the Company utilized CloudBoson Technologies Pvt. Ltd. (CloudBoson), formerly LegalSubmit Pvt. Ltd., a company owned by WorkSimplis Chief Software Engineer, to provide software development services.
• William Febbo, a member of the Board of Directors, entered into a consulting services agreement with the Company, pursuant to which he provides certain investor relations and strategic business development services.
• Robert Jindal, a member of the Board of Directors, entered into a consulting services agreement with the Company, pursuant to which Mr. Jindal provides certain investor relations and strategic business development services.
• Naveen Bhatia, a member of the Board of Directors, entered into a consulting services agreement with the Company, pursuant to which Mr. Bhatia provides certain investor relations and strategic business development services.

Stakeholder Impact

• Approval of the amended equity incentive plan could benefit employees, directors, and consultants by providing them with equity-based compensation.
• Stockholders could benefit from improved company performance due to the attraction and retention of key personnel.
• However, stockholders could also experience dilution if a large number of equity awards are granted.

Next Steps

• Stockholders will vote on the proposed amendment to the equity incentive plan at the Annual Meeting on June 14, 2024.

Key Dates

Keywords

equity incentive plan, stock options, restricted stock units, compensation, shares, LifeMD, amendment, stockholders